Navigation Links
Muscular Dystrophy Pipeline Market Global Analysis and Therapeutics Development for H2 2016
Date:11/22/2016

PUNE, India, November 22, 2016 /PRNewswire/ --

ReportsnReports.com adds "Muscular Dystrophy - Pipeline Review, H2 2016" to its store, providing comprehensive information on the therapeutics under development for Muscular Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Muscular Dystrophy and features dormant and discontinued projects.

Muscular dystrophy is a group of diseases in which muscle fibers are unusually susceptible to damage. These damaged muscles become progressively weaker. Symptoms usually appear before age 6 and may appear as early as infancy. They may include fatigue, learning difficulties, intellectual disability, muscle weakness and progressive difficulty walking.

Complete report on Global Muscular Dystrophy Market Research with 44 market data tables and 15 figures, spread across 144 pages is available at http://www.reportsnreports.com/reports/755879-muscular-dystrophy-pipeline-review-h2-2016.html .

Company Analysis and Positioning discussed in this research are Acceleron Pharma, Inc., AMO Pharma Limited, Asahi Kasei Pharma Corp., aTyr Pharma, Inc., Benitec Biopharma Limited, Bio Blast Pharma Ltd., Biophytis SAS, Corcept Therapeutics Incorporated, Evotec AG, F. Hoffmann-La Roche Ltd., Genethon, Ionis Pharmaceuticals, Inc., Marina Biotech, Inc., Medestea Research & Production S.p.A., Novogen Limited, Pfizer Inc., Prothelia, Inc., SanBio, Inc., Santhera Pharmaceuticals Holding AG, Sarepta Therapeutics, Inc., Selecta Biosciences, Inc., Strykagen Corporation, Takeda Pharmaceutical Company Limited and WAVE Life Sciences Ltd. Drug Profiles mentioned in this research are  ACE-083, Antisense Oligonucleotide to Inhibit DM1 Protein Kinase for Myotonic Dystrophy, Antisense RNAi Oligonucleotides for Myotonic Dystrophy, ATYR-1940, baliforsen, BIO-103, domagrozumab, Drugs for Merosin-Deficient Congenital Muscular Dystrophy Type 1A, elcatonin, Gene Therapy for Muscular Dystrophy and Liver Diseases, Gene Therapy to Activate Dysferlin for Duchenne and Limb Girdle Muscular Dystrophies, Gene Therapy to Activate Dysferlin for Dysferlinopathies, Gene Therapy to Activate Dystrophin for Muscular Dystrophy, IUCT-169, IUCT-290, IUCT-309, ketoprofen, LR-08, MED-1101, mexiletine hydrochloride, Oligonucleotide 1 to Target Dystrophia Myotonica Protein Kinase for Myotonic Dystrophy, Oligonucleotides to Inhibit DM1 Protein Kinase for Myotonic Dystrophy, omigapil, Pabparna, poloxamer, PRT-01, Recombinant Protein to Activate Utrophin for Muscular Dystrophies, RNAi Gene Therapy to Inhibit Myotilin for LGMD, RP-33, SB-308, SIWA-318, Small Molecule to Inhibit DUX4 for Muscular Dystrophy, Small Molecule to Target CUG RNA for Myotonic Dystrophy 1, Small Molecule to Target RNA for Myotonic Dystrophy, Small Molecules for Dysferlinopathies, Small Molecules for Facioscapulohumeral Muscular Dystrophy, Small Molecules for Myotonic Dystrophy, Small Molecules for Myotonic Dystrophy Type 1, Small Molecules to Activate SMCHD1 for Facioscapulohumeral Dystrophy, Small Molecules to Antagonize Glucocorticoid Receptor II for Muscular Dystrophy, Small Molecules to Inhibit MBNL1 for Myotonic Dystrophy Type I, Small Molecules to Target RNA for Myotonic Dystrophy, SRT-149, SRT-152, Stem Cell Therapy for Muscular Dystrophy, Stryka-232, Stryka-234, Stryka-425, Stryka-533, Stryka-978, tideglusib, trehalose, TXA-127, VAL-0411 and VAL-1205.

Order a opy of this report @ http://www.reportsnreports.com/purchase.aspx?name=755879 .

The Muscular Dystrophy (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Muscular Dystrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 2, 24 and 14 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 3 and 4 molecules, respectively.Muscular Dystrophy.

Muscular Dystrophy (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Explore more reports on Pharmaceuticals.

About Us:      

ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact:
Ritesh Tiwari
2nd floor, metropole,  Next to inox theatre, Bund garden road,
Pune-411001
Maharashtra, India.
Tel:  +1-888-391-5441
sales@reportsnreports.com

Connect With Us on:

Facebook:  https://www.facebook.com/ReportsnReports/

LinkedIn:  https://www.linkedin.com/company/reportsnreports

Twitter:  https://twitter.com/marketsreports

G+ / Google Plus: https://plus.google.com/111656568937629536321/posts

RSS/Feeds:  http://www.reportsnreports.com/feed/l-latestreports.xml



'/>"/>
SOURCE ReportsnReports
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Capricor Therapeutics Provides Enrollment Update on HOPE Clinical Trial in Duchenne Muscular Dystrophy
2. Deflazacort in Duchenne Muscular Dystrophy
3. Spinal Muscular Atrophy Market: Phase 3 Candidate ISIS-SMN Rx Shows Promising Results in Clinical Trial: Transparency Market Research
4. Marathon Pharmaceuticals Announces Nationwide Expanded Access Program for Patients with Duchenne Muscular Dystrophy (DMD)
5. Capricor Therapeutics Announces the First Patient with Duchenne Muscular Dystrophy-Related Cardiomyopathy Treated with CAP-1002 in the HOPE-Duchenne Phase I/II Clinical Trial
6. New Review of Idebenone as a Novel Therapeutic Approach for Duchenne Muscular Dystrophy
7. Ionis Pharmaceuticals Completes Target Enrollment for Nusinersen Phase 3 Study, CHERISH, in Children with Spinal Muscular Atrophy
8. Spinal Muscular Atrophy Program Advances with Additional Product Candidate Entering Clinical Development
9. Muscular Dystrophy Market Clinical Trials Report for H2 2015
10. Spinal Muscular Atrophy Market - Pipeline Analysis, Trends, Technology & Forecast 2015-2023
11. Parent Project Muscular Dystrophy Submits Results of Patient-Centered Benefit-Risk Assessment Study in Duchenne & Becker to FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... , March 28, 2017  Rosen Law Firm, ... of a class action lawsuit on behalf of purchasers ... KTOV ) pursuant and/or traceable to Kitov,s initial public ... and/or on the open market from November 20, 2015 ... Period"). The lawsuit seeks to recover damages for Kitov ...
(Date:3/28/2017)... 2017 Summary ... as a Key Component of Multichannel Marketing" provides ... landscape in the digital age. While the ... medical advancements, it has been much slower to ... on traditional channels and methods. However, the decreasing ...
(Date:3/28/2017)... -- Orexigen Therapeutics, Inc. (Nasdaq: OREX ) today ... and year ended December 31, 2016. ... Orexigen, beginning with the re-acquisition of the rights to ... team at Orexigen demonstrated remarkable focus, executing on a ... our Company while rewarding us full control of our ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... 29, 2017 , ... Patients interested in receiving quick and ... Jamie Cameron, with or without a referral. The FASTBRACES system is valued for ... each patient’s case, treatment with the FASTBRACES system could be completed in 120 ...
(Date:3/29/2017)... ... March 29, 2017 , ... Curio Wellness , a ... the finalization of the company’s executive management team with prominent executives from both inside ... Curio Wellness’ Chief Operating Officer, Ted Dumbauld , who has more than twenty ...
(Date:3/29/2017)... CA (PRWEB) , ... March 29, 2017 , ... Hamlin ... Northridge , is now offering laser dental treatments. Dental lasers are safe and effective ... dentistry expands patients’ options and can improve the overall quality of care. , Dr. ...
(Date:3/29/2017)... ... March 29, 2017 , ... VisualSP has helped over 1.5 ... the only option for on-premises installation of its Help System for SharePoint was at ... the system into the entire tenant. , The company recently released a modified ...
(Date:3/28/2017)... ... March 28, 2017 , ... Greenfield Advisors is ... his extensive knowledge of appraisals, property values, ad valorem taxation, and government policy ... industry for more than 40 years. , “Ruel is a great addition to ...
Breaking Medicine News(10 mins):